Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Quantitative Evaluation of BAFF, HMGB1, TLR 4 AND TLR 7 Expression in Patients with Relapsing Remitting Multiple Sclerosis.
Diffusion tensor imaging of the corticospinal tract and walking performance in multiple sclerosis.
Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis.
Evaluation of the effectiveness of home based or hospital based calisthenic exercises in patients with multiple sclerosis.
ACUTE RETINAL NECROSIS AND IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN A NATALIZUMAB-TREATED PATIENT WITH MULTIPLE SCLEROSIS.
Total-tau in cerebrospinal fluid of patients with multiple sclerosis decreases in secondary progressive stage of disease and reflects degree of brain atrophy.
Harnessing monocyte-derived macrophages to control central nervous system pathologies: No longer 'if' but 'how'
HLA-B7-Restricted EBV-Specific CD8+ T Cells Are Dysregulated in Multiple Sclerosis.
Switching to Gilenya® (fingolimod) from a standard interferon offers sustained freedom from disease activity for people with relapsing remitting multiple sclerosis
Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study.
Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis (DES)
Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis.
Immunotherapy of Multiple Sclerosis : The State of the Art.
The roles of cathelicidin LL-37 in immune defences and novel clinical applications.
Hypothyroidism in multiple sclerosis patient during fingolimod treatment.
ATX-MS-1467 in Multiple Sclerosis
Association between parasite infection and immune responses in multiple sclerosis.
Selective depression of low-release probability excitatory synapses by sodium channel blockers.
Gammaherpesvirus Latency Accentuates EAE Pathogenesis: Relevance to Epstein-Barr Virus and Multiple Sclerosis.
Dark microglia: A new phenotype predominantly associated with pathological states.
Brainstem PML lesion mimicking MS plaque in a natalizumab-treated MS patient.
Clinically meaningful performance benchmarks in MS: Timed 25-Foot Walk and the real world.
The best basic science paper in multiple sclerosis in 2014: Important role for the choroid plexus in the central nervous system entry of leukocytes.
The occurrence of dystonia in upper-limb multiple sclerosis tremor.
Multiple sclerosis.
Pages
« first
‹ previous
…
164
165
166
167
168
169
170
171
172
…
next ›
last »